Literature DB >> 33763450

Emerging Therapeutic Approaches to Combat COVID-19: Present Status and Future Perspectives.

Karthik Vivekanandhan1, Poornima Shanmugam1, Hamed Barabadi2, Vigneshwaran Arumugam3, Dharun Daniel Raj Daniel Paul Raj4, Manikandan Sivasubramanian5, Subbaiya Ramasamy6, Krishnan Anand7, Pandi Boomi8, Balakumar Chandrasekaran9, Selvaraj Arokiyaraj10, Muthupandian Saravanan11,12.   

Abstract

Coronavirus disease (COVID-19) has emerged as a fast-paced epidemic in late 2019 which is disrupting life-saving immunization services. SARS-CoV-2 is a highly transmissible virus and an infectious disease that has caused fear among people across the world. The worldwide emergence and rapid expansion of SARS-CoV-2 emphasizes the need for exploring innovative therapeutic approaches to combat SARS-CoV-2. The efficacy of some antiviral drugs such as remdesivir, favipiravir, umifenovir, etc., are still tested against SARS-CoV-2. Additionally, there is a large global effort to develop vaccines for the protection against COVID-19. Because vaccines seem the best solution to control the pandemic but time is required for its development, pre-clinical/clinical trials, approval from FDA and scale-up. The nano-based approach is another promising approach to combat COVID-19 owing to unique physicochemical properties of nanomaterials. Peptide based vaccines emerged as promising vaccine candidates for SARS-CoV-2. The study emphasizes the current therapeutic approaches against SARS-CoV-2 and some of the potential candidates for SARS-CoV-2 treatment which are still under clinical studies for their effectiveness against SARS-CoV-2. Overall, it is of high importance to mention that clinical trials are necessary for confirming promising drug candidates and effective vaccines and the safety profile of the new components must be evaluated before translation of in vitro studies for implementation in clinical use.
Copyright © 2021 Vivekanandhan, Shanmugam, Barabadi, Arumugam, Daniel Raj Daniel Paul Raj, Sivasubramanian, Ramasamy, Anand, Boomi, Chandrasekaran, Arokiyaraj and Saravanan.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; antiviral drugs; nano-based approaches; therapeutics; vaccines

Year:  2021        PMID: 33763450      PMCID: PMC7983051          DOI: 10.3389/fmolb.2021.604447

Source DB:  PubMed          Journal:  Front Mol Biosci        ISSN: 2296-889X


  75 in total

Review 1.  Gold nanoparticles and hepatitis B virus.

Authors:  Babak Negahdari; Mohammad Darvishi; Ali Asghar Saeedi
Journal:  Artif Cells Nanomed Biotechnol       Date:  2019-12       Impact factor: 5.678

2.  GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses.

Authors:  Michael K Lo; Robert Jordan; Aaron Arvey; Jawahar Sudhamsu; Punya Shrivastava-Ranjan; Anne L Hotard; Mike Flint; Laura K McMullan; Dustin Siegel; Michael O Clarke; Richard L Mackman; Hon C Hui; Michel Perron; Adrian S Ray; Tomas Cihlar; Stuart T Nichol; Christina F Spiropoulou
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

Review 3.  Nanotechnology for COVID-19: Therapeutics and Vaccine Research.

Authors:  Gaurav Chauhan; Marc J Madou; Sourav Kalra; Vianni Chopra; Deepa Ghosh; Sergio O Martinez-Chapa
Journal:  ACS Nano       Date:  2020-06-29       Impact factor: 15.881

Review 4.  Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19.

Authors:  Noura H Abd Ellah; Sheryhan F Gad; Khalid Muhammad; Gaber E Batiha; Helal F Hetta
Journal:  Nanomedicine (Lond)       Date:  2020-07-29       Impact factor: 5.307

5.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

6.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.

Authors:  Daniel Wrapp; Nianshuang Wang; Kizzmekia S Corbett; Jory A Goldsmith; Ching-Lin Hsieh; Olubukola Abiona; Barney S Graham; Jason S McLellan
Journal:  Science       Date:  2020-02-19       Impact factor: 47.728

7.  Viromimetic STING Agonist-Loaded Hollow Polymeric Nanoparticles for Safe and Effective Vaccination against Middle East Respiratory Syndrome Coronavirus.

Authors:  Leon Chien-Wei Lin; Chen-Yu Huang; Bing-Yu Yao; Jung-Chen Lin; Anurodh Agrawal; Abdullah Algaissi; Bi-Hung Peng; Yu-Han Liu; Ping-Han Huang; Rong-Huay Juang; Yuan-Chih Chang; Chien-Te Tseng; Hui-Wen Chen; Che-Ming Jack Hu
Journal:  Adv Funct Mater       Date:  2019-04-12       Impact factor: 18.808

8.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

Review 9.  Nano-Biomimetic Drug Delivery Vehicles: Potential Approaches for COVID-19 Treatment.

Authors:  Bwalya A Witika; Pedzisai A Makoni; Larry L Mweetwa; Pascal V Ntemi; Melissa T R Chikukwa; Scott K Matafwali; Chiluba Mwila; Steward Mudenda; Jonathan Katandula; Roderick B Walker
Journal:  Molecules       Date:  2020-12-16       Impact factor: 4.411

10.  Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.

Authors:  Dong Huang; He Yu; Ting Wang; Huan Yang; Rong Yao; Zongan Liang
Journal:  J Med Virol       Date:  2020-07-14       Impact factor: 20.693

View more
  6 in total

1.  Editorial: Pharmacological and Biochemical Perspectives of Kinase Inhibitors in Cancer and COVID-19 Therapeutics, Volume I.

Authors:  Balakumar Chandrasekaran; Muthupandian Saravanan
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

Review 2.  A systemic review on liquid crystals, nanoformulations and its application for detection and treatment of SARS - CoV- 2 (COVID - 19).

Authors:  Ayushi Rastogi; Abhilasha Singh; Kaustubh Naik; Archana Mishra; Shilpi Chaudhary; Rajiv Manohar; Avanish Singh Parmar
Journal:  J Mol Liq       Date:  2022-07-08       Impact factor: 6.633

3.  Defective ORF8 dimerization in SARS-CoV-2 delta variant leads to a better adaptive immune response due to abrogation of ORF8-MHC1 interaction.

Authors:  Indra Singh; Armi M Chaudhari; Madhvi Joshi; Amrutlal Patel; Chaitanya Joshi
Journal:  Mol Divers       Date:  2022-03-03       Impact factor: 2.943

4.  Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2.

Authors:  Neslihan Pakize Taşlı; Zeynep Burçin Gönen; Oğuz Kaan Kırbaş; Nur Seda Gökdemir; Batuhan Turhan Bozkurt; Buse Bayrakcı; Derya Sağraç; Ezgi Taşkan; Sevda Demir; Nur Ekimci Gürcan; Melike Bayındır Bilgiç; Ömer Faruk Bayrak; Hazel Yetişkin; Büşra Kaplan; Shaikh Terkıs Islam Pavel; Gökçen Dinç; Müge Serhatlı; Gamze Çakırca; Ahmet Eken; Vedat Aslan; Mehmet Yay; Musa Karakukcu; Ekrem Unal; Fethi Gül; Kemal Erdem Basaran; Yusuf Ozkul; Fikrettin Şahin; Olcay Y Jones; Şaban Tekin; Aykut Özdarendeli; Mustafa Cetin
Journal:  Front Immunol       Date:  2022-03-24       Impact factor: 7.561

5.  Receptor-binding domain-anchored peptides block binding of severe acute respiratory syndrome coronavirus 2 spike proteins with cell surface angiotensin-converting enzyme 2.

Authors:  Ting Wang; Jie Xu; Beibei Wang; Yulian Wang; Wei Zhao; Bin Xiang; Yuhua Xue; Quan Yuan; Yiqiang Wang
Journal:  Front Microbiol       Date:  2022-09-13       Impact factor: 6.064

Review 6.  Seaweed Sulfated Polysaccharides against Respiratory Viral Infections.

Authors:  Mehwish Jabeen; Mélody Dutot; Roxane Fagon; Bernard Verrier; Claire Monge
Journal:  Pharmaceutics       Date:  2021-05-16       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.